Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineered antibodies as pharmacological tools.

E Haber1

  • 1Division of Biological Sciences, Harvard School of Public Health, Boston, MA 02115.

Immunological Reviews
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-Area Epitaxial Mott Insulating 1T-TaSe<sub>2</sub> Monolayer on GaP(111)B.

Nano letters·2023
Same author

Outcomes of renal replacement therapy in the critically ill with COVID-19.

Medicina intensiva·2021
Same author

Outcomes of renal replacement therapy in the critically ill with COVID-19.

Medicina intensiva·2021
Same author

Use of controlled vignettes in evaluation: does type of response method make a difference?

Evaluation and program planning·2013
Same author

The impact of biotechnology on advances in cardiovascular medicine.

Trends in cardiovascular medicine·2011
Same author

Route of administration-dependent anti-inflammatory effect of liposomal alendronate.

Journal of controlled release : official journal of the Controlled Release Society·2010

Scientists are engineering antibody fragments for targeted drug delivery. This involves creating fusion proteins with enhanced potency and specificity for potential therapeutic applications.

Area of Science:

  • Biotechnology
  • Immunology
  • Protein Engineering

Background:

  • Antibody engineering enables the creation of targeted therapeutic molecules.
  • Single-chain antibody combining sites can be fused with functional domains.

Purpose of the Study:

  • To review advancements in engineering antibody-based targeting molecules.
  • To illustrate the construction and application of antibody-fusion proteins.

Main Methods:

  • Site-directed mutagenesis and in vitro selection for antibody affinity tuning.
  • Construction of single-chain antigen-binding domains.
  • Development of antibody-enzyme fusion proteins.

Main Results:

  • Single point mutations in digoxin-specific antibodies significantly altered antigen recognition.

Related Experiment Videos

  • An anti-fibrin antibody-single-chain urokinase fusion protein demonstrated enhanced potency and specificity.
  • Engineered fusion proteins show promise for increased therapeutic efficacy and reduced toxicity.

    • Conclusions:

    • Antibody engineering offers a viable strategy for developing targeted pharmacological agents.
    • Fusion proteins combining antibody-based targeting with enzymatic activity hold significant therapeutic potential.